Celgene and Evotec both invested in Exscientia, as the automated drug discovery services provider added Roche to its roster of development partners.

Exscientia, a UK-based drug discovery technology developer, received $26m on Monday in a series B round backed by pharmaceutical company Celgene, medicine developer Evotec and GT Healthcare Capital Partners. Founded in 2012 as a spinout of University of Dundee, Exscientia has devised an automated drug discovery technology that applies artificial intelligence to insights gained from…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.